Logo Image
News|Webcasts|August 2, 2024

Cell and Gene Therapy Clinical Development: Strategies From Design to Delivery

Author(s)IQVIA

Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST

Join experts to explore regulatory strategies, clinical challenges, and operational models that speed up trials and bring patient treatments.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/design-to-delivery
Event overview

Explore how groundbreaking cell and gene therapies (CAGTs) are revolutionizing previously untreatable diseases to improve the quality of life for patients. Join experts from IQVIA Biotech and IQVIA as they address the current state of CAGTs, regulatory strategies that move innovation forward and critical clinical development decisions.

Learning Objectives

  • Gain insights into the dynamic regulatory landscape of CAGT trials and issues biotech sponsors should consider.
  • Understand the challenges associated with CAGT clinical development, the advantages of early planning and the data-driven decisions crucial for the successful development of CAGTs.
  • Discover how efficient operational models and expert cross-functional CAGT teams reduce complexity and accelerate clinical trials.


Speakers:

Erin Finot, MS, MBA
Vice President, Immuno-Oncology and CAGT
IQVIA Biotech

Erin Finot, MS, MBA, is vice president of immuno-oncology and CAGT at IQVIA Biotech. She leads strategic efforts to ensure high-quality services and innovative trial solutions for biotech sponsors. With over 20 years of experience in global clinical research and drug development, Erin's therapeutic expertise guides sponsors through the dynamic landscape of immuno-oncology and cell and gene therapies.

Diego Correa, MD, PhD, MSc
Vice President and Global Head, Cell and Gene Therapy Center of Excellence
IQVIA

Diego Correa, MD, PhD, MSc, is vice president and global head of the Cell and Gene Therapy Center of Excellence at IQVIA. He has more than two decades of research experience in cell therapy, tissue engineering, and regenerative medicine. His expertise guides clinical trial sponsors and study teams toward innovative, data-driven solutions for CAGT studies. Dr. Correa has 60-plus peer-reviewed publications and actively contributes to international scientific organizations.


Patrick Brady, PharmD
Global Head, Therapeutic Innovation and Regulatory Science
IQVIA

Patrick Brady, PharmD, is global head of therapeutic innovation and regulatory science at IQVIA. With more than two decades of experience in regulatory affairs in the biopharmaceutical industry, Dr. Brady regularly advises R&D leadership and project teams on global drug development strategies, emerging technologies, and the changing regulatory landscape and policies to help inform strategies and decision-making.


Register Free: https://www.appliedclinicaltrialsonline.com/act_w/design-to-delivery

Related to this article

View more
Introducing The Human Side of Clinical Trials
Introducing The Human Side of Clinical Trials
This pilot episode of The Human Side of Clinical Trials introduces a framework from Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., exploring why operational failures in clinical trials often trace back to gaps in human readiness rather than process design alone.
Read more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Read more
What It Actually Means to Embed the Patient Voice in Trial Design
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
Read more
© ABCDstock - © ABCDstock - stock.adobe.com
Beyond Patient Centricity: What Rare Disease Research Gets Right
Patient-centricity remains largely consultative in most clinical research, yet rare disease communities demonstrate that genuine partnership from protocol inception improves feasibility, reduces unnecessary burden, and identifies outcomes that matter to patients themselves.
Read more